Literature DB >> 19615914

Laparoscopic ischaemic conditioning of the stomach may reduce gastric-conduit morbidity following total minimally invasive oesophagectomy.

Richard G Berrisford1, Darmarajah Veeramootoo, Rajeev Parameswaran, Rakesh Krishnadas, Shahjehan A Wajed.   

Abstract

OBJECTIVE: Oesophagectomy, whether open or minimal access, is associated with a significant incidence of gastric-conduit-related complications. Previous animal and human studies suggest that ischaemic conditioning of the stomach prior to oesophagectomy improves perfusion of the gastric conduit. We have adopted laparoscopic ligation of the left gastric artery 2 weeks prior to minimally invasive oesophagectomy, having identified a relative high incidence of gastric-tube complications through a cumulative summation (CUSUM) analysis.
METHODS: This study included 77 consecutive patients who underwent a Total MIO (thoracoscopic oesophageal mobilisation, laparoscopic gastric tube formation, cervical anastomosis). The ligation group comprised 22 consecutive patients, excluding those with middle-third squamous tumours or early-stage adenocarcinoma, who underwent ligation 2 weeks prior to MIO at staging laparoscopy. The control group comprised 55 patients who did not undergo ischaemic conditioning in this way. We have defined conduit-related complications as: leak managed conservatively (L); tip necrosis requiring resection and re-anastomosis (TN) and conduit necrosis needing resection and oesophagostomy (CN). The values are reported as medians. The effect of ligation of the left gastric artery was followed with a CUSUM analysis.
RESULTS: Ligation was performed 15.5 days pre-operatively (median). There were no complications and the length of hospital stay was 1 day. Although gastric mobilisation at MIO was technically more difficult after ligation, there was no significant difference in operating time (ligation, 407 min; control, 425 min) or blood loss (ligation and control, 500 ml). There was less gastric-conduit morbidity in the ligation group (two of 22, 10%; one L, one CN) compared with the control group (11 of 55, 20%; four L, five TN, two CN), but these differences did not reach statistical significance (p=0.211 and p=0.176 Fisher's exact test). The CUSUM analysis showed that during ligation of the left gastric artery, conservatively treated gastric-conduit-related morbidity (leak, resection and re-anastomosis or conduit necrosis) remained within safe limits (10%). Conduit-related-morbidity increased after stopping ligation.
CONCLUSION: In this non-randomised clinical setting, our results suggest that ischaemic conditioning of the stomach prior to MIO is safe. There is a trend to reduced morbidity related to gastric-conduit ischaemia, which was demonstrated by a CUSUM analysis. A randomised trial is needed before ligation of the left gastric artery can be routinely recommended.

Entities:  

Mesh:

Year:  2009        PMID: 19615914     DOI: 10.1016/j.ejcts.2009.01.055

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  14 in total

1.  Randomized controlled trial of laparoscopic gastric ischemic conditioning prior to minimally invasive esophagectomy, the LOGIC trial.

Authors:  Darmarajah Veeramootoo; Angela C Shore; Shahjehan A Wajed
Journal:  Surg Endosc       Date:  2012-02-01       Impact factor: 4.584

2.  Minimally invasive esophagectomy with extracorporeal gastric conduit creation--how I do it.

Authors:  Francesco Palazzo; Nathaniel R Evans; Ernest L Rosato
Journal:  J Gastrointest Surg       Date:  2013-07-09       Impact factor: 3.452

3.  Esophageal replacement following gastric devascularization is safe, feasible, and may decrease anastomotic complications.

Authors:  Kyle A Perry; C Kristian Enestvedt; Thai H Pham; James P Dolan; John G Hunter
Journal:  J Gastrointest Surg       Date:  2010-05-15       Impact factor: 3.452

4.  Minimally invasive esophagectomy with two-field lymphadenectomy.

Authors:  Darmarajah Veeramootoo; Clare Taylor; Shahjehan A Wajed
Journal:  Surg Endosc       Date:  2011-05-14       Impact factor: 4.584

Review 5.  Gastric Preconditioning in Advance of Esophageal Resection-Systematic Review and Meta-Analysis.

Authors:  Patrick Heger; Susanne Blank; Markus K Diener; Alexis Ulrich; Thomas Schmidt; Markus W Büchler; André L Mihaljevic
Journal:  J Gastrointest Surg       Date:  2017-04-24       Impact factor: 3.452

6.  Evaluation of hyperspectral imaging (HSI) for the measurement of ischemic conditioning effects of the gastric conduit during esophagectomy.

Authors:  Hannes Köhler; Boris Jansen-Winkeln; Marianne Maktabi; Manuel Barberio; Jonathan Takoh; Nico Holfert; Yusef Moulla; Stefan Niebisch; Michele Diana; Thomas Neumuth; Sebastian M Rabe; Claire Chalopin; Andreas Melzer; Ines Gockel
Journal:  Surg Endosc       Date:  2019-01-23       Impact factor: 4.584

7.  Vascular anatomy of the stomach related to resection procedures strategy.

Authors:  V Prudius; V Procházka; Z Pavlovský; D Prudius; Z Kala
Journal:  Surg Radiol Anat       Date:  2016-09-21       Impact factor: 1.246

8.  Ischemic conditioning shows a time-dependant influence on the fate of the gastric conduit after minimally invasive esophagectomy.

Authors:  Darmarajah Veeramootoo; Angela C Shore; Beverley Shields; Rakesh Krishnadas; Martin Cooper; Richard G Berrisford; Shahjehan A Wajed
Journal:  Surg Endosc       Date:  2009-12-09       Impact factor: 4.584

9.  Video. Surgical optimisation of the gastric conduit for minimally invasive oesophagectomy.

Authors:  Shahjehan A Wajed; Darmarajah Veeramootoo; Angela C Shore
Journal:  Surg Endosc       Date:  2011-08-20       Impact factor: 4.584

10.  Laparoscopic ischemic conditioning of the stomach increases neovascularization of the gastric conduit in patients undergoing esophagectomy for cancer.

Authors:  Thai H Pham; Shelby D Melton; Patrick J McLaren; Ali A Mokdad; Sergio Huerta; David H Wang; Kyle A Perry; Hope L Hardaker; James P Dolan
Journal:  J Surg Oncol       Date:  2017-05-29       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.